var data={"title":"Bicarbonate therapy in lactic acidosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Bicarbonate therapy in lactic acidosis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/contributors\" class=\"contributor contributor_credentials\">Michael Wiederkehr, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/contributors\" class=\"contributor contributor_credentials\">Michael Emmett, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/contributors\" class=\"contributor contributor_credentials\">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/contributors\" class=\"contributor contributor_credentials\">John P Forman, MD, MSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 14, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H25392892\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lactic acidosis causes a decrease in serum bicarbonate concentration that is similar in magnitude to the increase in the lactate concentration. Lactate is a metabolizable organic anion that, when oxidized, will generate bicarbonate. Thus, if the stimulus to lactic acid production is eliminated by successful treatment of the underlying disease (eg, restoration of perfusion in a patient with shock), oxidative processes will metabolize the accumulated lactate and regenerate bicarbonate. This will correct the metabolic acidosis and reduce the anion gap.</p><p>The role of exogenous bicarbonate therapy in patients with lactic acidosis is controversial [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/1-5\" class=\"abstract_t\">1-5</a>]. Most, but not all, experts believe that it is appropriate to use bicarbonate in acutely ill patients with profound lactic acidosis and acidemia (arterial pH less than 7.1). Such severe acidemia may produce hemodynamic instability as a result of reduced left ventricular contractility, arterial vasodilation, and impaired responsiveness to catecholamines [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/1,5-10\" class=\"abstract_t\">1,5-10</a>].</p><p>The role of bicarbonate therapy and alternative buffering agents in patients with lactic acidosis will be discussed in this topic. The causes of lactic acidosis, the approach to the adult with metabolic acidosis, and the treatment of shock in adults are presented elsewhere. (See <a href=\"topic.htm?path=causes-of-lactic-acidosis\" class=\"medical medical_review\">&quot;Causes of lactic acidosis&quot;</a> and <a href=\"topic.htm?path=approach-to-the-adult-with-metabolic-acidosis\" class=\"medical medical_review\">&quot;Approach to the adult with metabolic acidosis&quot;</a> and <a href=\"topic.htm?path=treatment-of-hypovolemia-or-hypovolemic-shock-in-adults\" class=\"medical medical_review\">&quot;Treatment of hypovolemia or hypovolemic shock in adults&quot;</a>.)</p><p>The use of bicarbonate dialysis to correct lactic acidosis caused by <a href=\"topic.htm?path=metformin-drug-information\" class=\"drug drug_general\">metformin</a> is discussed separately. (See <a href=\"topic.htm?path=metformin-poisoning\" class=\"medical medical_review\">&quot;Metformin poisoning&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12631273\"><span class=\"h1\">OVERVIEW OF THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following general approach applies to the use of bicarbonate therapy in patients with lactic acidosis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Who should be treated &ndash; In our opinion, bicarbonate therapy should be initiated when lactic acidosis has generated severe acidemia (pH less than 7.1 but generally not those with higher values). (See <a href=\"#H12631281\" class=\"local\">'Which patients should receive bicarbonate therapy'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Goals of therapy &ndash; The primary aim of therapy is reversal of the underlying disease<strong> </strong>(eg, shock). When using bicarbonate therapy in patients with lactic acidosis and severe acidemia, the aim is to maintain the arterial pH above 7.1 until the primary process causing the metabolic acidosis can be reversed. (See <a href=\"#H12631289\" class=\"local\">'Therapeutic goal'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Potential harms &ndash; Rapid infusions of <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> may increase the PCO2, accelerate the production of lactate, lower the ionized calcium, expand the extracellular space, and raise the serum sodium concentration. There is little evidence that any alternative buffering agents are superior to sodium bicarbonate therapy. (See <a href=\"#H12631806\" class=\"local\">'Potential harms of bicarbonate and alternative agents'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Approach &ndash; In adequately ventilated patients with lactic acidosis and severe acidemia, we give 1 to 2 <span class=\"nowrap\">mEq/kg</span> <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> as an intravenous bolus. We repeat this dose after 30 to 60 minutes if the pH is still below 7.1. (See <a href=\"#H12631304\" class=\"local\">'Approach'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H12631281\"><span class=\"h1\">WHICH PATIENTS SHOULD RECEIVE BICARBONATE THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest that patients with lactic acidosis and severe acidemia (pH less than 7.1 and serum bicarbonate level 6 <span class=\"nowrap\">mEq/L</span> or less) receive bicarbonate therapy. If the patient's pH is 7.1 or lower and the serum bicarbonate level is greater than 6 <span class=\"nowrap\">mEq/L,</span> then this indicates that the PCO2 is greater than 20 mmHg, which signifies inadequate ventilation. Mechanical ventilation should be considered for these patients (who have mixed metabolic and respiratory acidosis) because administration of <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> in this setting will likely worsen the respiratory acidosis.</p><p>There is no good evidence for, or against, <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> therapy when the pH is below 7.1. However, we suggest its use in such patients because it may <span class=\"nowrap\">treat/prevent</span> the following adverse clinical effects of acidemia, each of which can produce hemodynamic instability [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/1,5-11\" class=\"abstract_t\">1,5-11</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduced left ventricular contractility</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Arrhythmias</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Arterial vasodilation and venoconstriction</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Impaired responsiveness to catecholamine vasopressors</p><p/><p>In addition, relatively small bicarbonate concentration changes will have great pH impact when the serum bicarbonate concentration is markedly reduced (doubling the bicarbonate concentration, for example from 2 to 4 <span class=\"nowrap\">mEq/L,</span> without a change in PCO2 will raise the pH by 0.3 units). <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">Sodium bicarbonate</a> infusion will also expand the extracellular fluid (ECF) volume, an effect that can be beneficial or deleterious, depending upon the patient's pre-infusion volume status.</p><p>However, we do <strong>not</strong> recommend bicarbonate therapy in patients with less severe acidosis (pH 7.1 or greater). Two randomized trials failed to find a benefit of bicarbonate therapy in critically ill patients with lactic acidosis and pH values greater than 7.1:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a crossover study, 14 patients with lactic acidosis (serum bicarbonate less than 17 <span class=\"nowrap\">mmol/L</span> and arterial lactate greater than 2.5 <span class=\"nowrap\">mmol/L)</span> in a single intensive care unit received, in random order, 2 <span class=\"nowrap\">mmol/kg</span> of <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> and an equivalent dose of sodium chloride [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/12\" class=\"abstract_t\">12</a>]. Bicarbonate therapy produced a significant rise in arterial pH (from 7.22 to 7.36) and serum bicarbonate (from 12 to 18 <span class=\"nowrap\">mmol/L)</span>. However, the hemodynamic responses to sodium bicarbonate and sodium chloride, including cardiac output, mean arterial pressure, and pulmonary capillary wedge pressure, were identical.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a similarly designed trial of 10 patients with lactic acidosis, <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> (1 <span class=\"nowrap\">mmol/kg)</span> and an equivalent dose of sodium chloride were administered in random order [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/10\" class=\"abstract_t\">10</a>]. Bicarbonate therapy significantly increased the arterial pH (from 7.16 to 7.21) and serum bicarbonate (from 16 to 19 <span class=\"nowrap\">mmol/L)</span>. Again, the infusion of sodium bicarbonate and sodium chloride produced similar changes in cardiac output, mean arterial pressure, and pulmonary artery pressure.</p><p/><p>These two trials were too small to detect a minor benefit of bicarbonate therapy; in addition, patients with severe acidemia were not represented. Thus, we and other experts continue to use bicarbonate therapy in patients who have an arterial pH less than 7.1. However, bicarbonate therapy requires adequate ventilation as discussed below. (See <a href=\"#H12631806\" class=\"local\">'Potential harms of bicarbonate and alternative agents'</a> below.)</p><p>The use of bicarbonate therapy in patients with cardiac arrest is presented separately. (See <a href=\"topic.htm?path=therapies-of-uncertain-benefit-in-basic-and-advanced-cardiac-life-support#H18\" class=\"medical medical_review\">&quot;Therapies of uncertain benefit in basic and advanced cardiac life support&quot;, section on 'Sodium bicarbonate therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H12631289\"><span class=\"h1\">THERAPEUTIC GOAL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The primary aim of therapy is <strong>reversal of the underlying disease </strong>(eg, shock, sepsis). Tissue hypoxia may dramatically increase lactic acid production, often coupled with reduced metabolic clearance of lactate by the liver, heart, and kidneys. This combination of overproduction and underutilization can easily overwhelm any attempt to increase the serum bicarbonate with exogenously administered alkali. In fact, as discussed below, alkali therapy may accelerate lactic acid production. Thus, unless the pathologic process causing the excessive production of lactic acid can be reversed, any beneficial effect of exogenous bicarbonate will be transient. (See <a href=\"#H12631806\" class=\"local\">'Potential harms of bicarbonate and alternative agents'</a> below.)</p><p>When using bicarbonate therapy in patients with lactic acidosis and severe acidemia, we aim to maintain the arterial pH above 7.1 until the primary process causing the metabolic acidosis can be reversed.</p><p class=\"headingAnchor\" id=\"H12631806\"><span class=\"h1\">POTENTIAL HARMS OF BICARBONATE AND ALTERNATIVE AGENTS</span></p><p class=\"headingAnchor\" id=\"H12632674\"><span class=\"h2\">Potential harms of bicarbonate therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rapid infusions of <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> have a number of potentially adverse effects:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased arterial and tissue capillary PCO2</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acceleration of lactate generation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduced ionized calcium</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypernatremia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extracellular fluid (ECF) volume expansion</p><p/><p class=\"headingAnchor\" id=\"H12632681\"><span class=\"h3\">Increased PCO2</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The infused bicarbonate must undergo several metabolic steps to effectively raise the pH. First, it combines with a hydrogen ion to form H2CO3 (carbonic acid). Second, H2CO3 dehydrates to CO2, and H2O and CO2 must be removed from the tissue bed and the body by circulation and respiration. If the CO2 generated by infused bicarbonate is not efficiently removed, then the resulting increase in PCO2 will prevent carbonic acid dehydration and the pH will not increase. Consequently, adequate perfusion and ventilation is a prerequisite to the effective use of exogenous bicarbonate.</p><p>Even with adequate ventilation, the PCO2 is likely to rise at the local tissue level when bicarbonate is infused. Because CO2 readily penetrates cell membranes, this increase in tissue PCO2 may worsen intracellular acidosis even as arterial blood pH increases. This dissociation between tissue and systemic arterial acid-base parameters is magnified in patients with circulatory failure [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/13,14\" class=\"abstract_t\">13,14</a>].</p><p>The cerebrospinal fluid (CSF) pH may also fall when bicarbonate is infused for two reasons: first, the mechanism described above increases the PCO2 locally in the brain and CSF; second, amelioration of systemic acidemia (ie, the rise in arterial blood pH) diminishes the drive for hyperventilation, causing the systemic PCO2 to increase. Any systemic <span class=\"nowrap\">and/or</span> local increase in PCO2 will be quickly reflected within the CSF. By contrast, an increased blood bicarbonate concentration is only slowly transmitted to the CSF. Because CSF bicarbonate concentration does not rise as rapidly as the CSF PCO2, a &quot;paradoxical&quot; reduction in CSF pH may occur and be associated with neurologic deterioration [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/15,16\" class=\"abstract_t\">15,16</a>].</p><p class=\"headingAnchor\" id=\"H12632935\"><span class=\"h3\">Acceleration of lactate generation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acidemia may act as a &quot;brake&quot; on lactic acid generation by inhibiting glycolysis, mediated by a reduction in the activity of the enzyme, phosphofructokinase [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/17\" class=\"abstract_t\">17</a>]. Thus, increasing pH with exogenous bicarbonate may accelerate the production of lactate.</p><p class=\"headingAnchor\" id=\"H12632964\"><span class=\"h3\">Effects on calcium, sodium, and extracellular fluid volume</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An increase in pH can decrease the ionized calcium concentration, which may adversely affect cardiac function [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/9,18\" class=\"abstract_t\">9,18</a>]. Because <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> is usually infused as a hypertonic solution, a 50 mL ampule containing 50 mEq of sodium bicarbonate (1000 <span class=\"nowrap\">mmol/L)</span> will raise the serum sodium concentration of a 70 kg person by approximately 1 <span class=\"nowrap\">mEq/L</span> and expand the ECF volume by approximately 250 mL.</p><p class=\"headingAnchor\" id=\"H12631930\"><span class=\"h2\">Alternatives to bicarbonate therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The limitations and potential deleterious effects of <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> therapy in patients with lactic acidosis have prompted investigation into the use of alternative buffering agents, such as <a href=\"topic.htm?path=tromethamine-tham-united-states-not-available-drug-information\" class=\"drug drug_general\">tromethamine</a> (tris-hydroxymethyl aminomethane; also called THAM, TRIS, and trometamol) and carbicarb, as well as dichloroacetate (DCA), which is an agent that accelerates lactate metabolism. However, <strong>none</strong> of these alternative agents have shown clinical benefit in patients with lactic acidosis.</p><p class=\"headingAnchor\" id=\"H12632114\"><span class=\"h3\">Tromethamine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tromethamine-tham-united-states-not-available-drug-information\" class=\"drug drug_general\">Tromethamine</a> (tris-hydroxymethyl aminomethane; also called THAM, TRIS, and trometamol) is an amino alcohol which buffers protons by virtue of its amine (NH2) moiety (pKa = 7.7) via the following reactions [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/19\" class=\"abstract_t\">19</a>]:</p><div class=\"formulaContainer\"><div class=\"formula\"><p> &#160;THAM-NH2 + H+ &#160;= &#160;THAM-NH3+</p></div></div><p>Unlike bicarbonate, which generates CO2 when it acts as a buffer, THAM consumes CO2:</p><div class=\"formulaContainer\"><div class=\"formula\"><p> &#160;THAM-NH2 + H2O + CO2 &#160;= &#160;THAM-NH3+ + HCO3-</p></div></div><p>The urinary clearance of protonated THAM salts is slightly greater than urinary clearance of creatinine. To the extent THAM-NH3+ is excreted in the urine with chloride, this represents net acid excretion. However, if THAM-NH3+ is excreted with HCO3-, then no net acid excretion occurs. Thus, THAM can increase the buffering capacity of blood without generating CO2 but is less effective in anuric patients. Reported toxicities of THAM include hyperkalemia, hypoglycemia, and respiratory depression; the last complication may be due to the ability of THAM to rapidly increase the pH and decrease the PCO2 in the central nervous system. (See <a href=\"topic.htm?path=control-of-ventilation\" class=\"medical medical_review\">&quot;Control of ventilation&quot;</a>.)</p><p>THAM has been used to treat severe acidemia due to sepsis, permissive hypercapnia, diabetic ketoacidosis, renal tubular acidosis, gastroenteritis, and drug intoxications [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/19-21\" class=\"abstract_t\">19-21</a>]. However, THAM has <strong>not</strong> been evaluated in clinical trials involving patients with lactic acidosis. Thus, the efficacy and safety of THAM in such patients is unknown.</p><p class=\"headingAnchor\" id=\"H12632121\"><span class=\"h3\">Carbicarb</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Another potential and perhaps more effective alternative to <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> is an equimolar mixture of sodium carbonate (Na2CO3) and sodium bicarbonate called &quot;carbicarb&quot; [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/22\" class=\"abstract_t\">22</a>]. Sodium carbonate in the mixture reacts with carbonic acid (H2CO3) to generate bicarbonate via the following reaction [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/22,23\" class=\"abstract_t\">22,23</a>]:</p><div class=\"formulaContainer\"><div class=\"formula\"><p> &#160;CO3(2-) + H2CO3 &#160;= &#160;2 HCO3-</p></div></div><p>Thus, the carbonate component of carbicarb consumes H2CO3 (or CO2) while the HCO3 component and the newly generated HCO3 will form CO2 when protons are buffered. Consequently, the total amount of CO2 which is generated is approximately two-thirds the amount that would be generated by an equimolar amount of HCO3 alone. The mixture of sodium carbonate and <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> is utilized instead of sodium carbonate alone because a solution of pure sodium carbonate is too caustic to be intravenously infused [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/24\" class=\"abstract_t\">24</a>]. The risks of hypertonicity and hypervolemia are similar to those of sodium bicarbonate [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/22-24\" class=\"abstract_t\">22-24</a>].</p><p>Carbicarb has been evaluated in animals, with inconsistent benefit compared with <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/24-27\" class=\"abstract_t\">24-27</a>]. One human study of 36 surgical patients with metabolic acidosis compared the effects of sodium bicarbonate with carbicarb [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/28\" class=\"abstract_t\">28</a>]. No benefit was observed. Carbicarb is not currently available in the United States.</p><p class=\"headingAnchor\" id=\"H12632128\"><span class=\"h3\">Dichloroacetate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dichloroacetate (DCA) is another investigational drug that has been studied in lactic acidosis. It increases the activity of the enzyme, pyruvate dehydrogenase, which accelerates mitochondrial oxidation of pyruvate and thereby also accelerates lactate metabolism [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/29,30\" class=\"abstract_t\">29,30</a>]. Although several early human and animal studies were promising, a clinical trial in humans with lactic acidosis showed no mortality benefit or hemodynamic improvement despite a fall in lactic acid levels and improvement in arterial pH [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/31\" class=\"abstract_t\">31</a>]. DCA has been studied in patients with congenital mitochondrial defects associated with chronic lactic acidosis and as an anti-neoplastic agent [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/32-34\" class=\"abstract_t\">32-34</a>]. It is not currently available in the United States.</p><p class=\"headingAnchor\" id=\"H12631304\"><span class=\"h1\">APPROACH</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In critically ill patients with severe lactic acidosis, which has resulted in severe acidemia (pH less than 7.1 and serum bicarbonate concentration 6 <span class=\"nowrap\">mEq/L</span> or less), we suggest the following approach in regard to bicarbonate therapy:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Assure that the patient is adequately ventilated; this is a prerequisite to the effective use of exogenous bicarbonate in patients with lactic acidosis. In non-intubated patients with severe acidemia, an appropriate ventilatory response should reduce the PCO2 to at least 15 mmHg and often to 10 to 12 mmHg.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If bicarbonate administration raises the pH, this can reduce the ionized calcium concentration and have adverse hemodynamic consequences. Ideally, the ionized calcium should be measured and treated if it falls. However, in many facilities, this measurement may not be readily available within the required time frame. Under such circumstances, if the blood pressure falls or does not improve, and if the ionized calcium could be low, then empiric calcium infusion should be considered [<a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If ventilation is adequate, the patient with severe lactic acidosis (pH less than 7.1) should be given an intravenous <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> bolus of 1 to 2 <span class=\"nowrap\">mEq/kg</span> body weight. The serum electrolytes and blood pH should be measured 30 to 60 minutes later, and the dose of sodium bicarbonate can be repeated if severe lactic acidosis (pH less than 7.1) persists.</p><p/><p class=\"bulletIndent1\">We prefer this empiric approach to the dosing of bicarbonate, rather than calculating the dose based upon the &quot;bicarbonate distribution space.&quot; The bicarbonate distribution space is a virtual concept and not a true anatomic space. Its size varies markedly with the severity of the metabolic acidosis. In addition, since bicarbonate can be rapidly generated or decomposed, its apparent distribution space can change dramatically.</p><p/><p class=\"headingAnchor\" id=\"H709696017\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-fluid-and-electrolyte-disorders\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Fluid and electrolyte disorders&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12631328\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The role of exogenous bicarbonate therapy in patients with lactic acidosis is controversial. Most experts believe that it is appropriate to use bicarbonate in acutely ill patients with profound lactic acidosis that has generated an arterial pH less than 7.1 and a serum bicarbonate of 6 <span class=\"nowrap\">mEq/L</span> or less. Such severe acidemia may produce hemodynamic instability as a result of reduced left ventricular contractility, arterial vasodilation, and impaired responsiveness to catecholamines. (See <a href=\"#H25392892\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The following general approach applies to the use of bicarbonate therapy in patients with lactic acidosis (see <a href=\"#H12631273\" class=\"local\">'Overview of therapy'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The primary aim of therapy for lactic acidosis is reversal of the underlying disease<strong> </strong>(eg, shock). (See <a href=\"#H12631289\" class=\"local\">'Therapeutic goal'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We suggest that patients with lactic acidosis, which has generated severe acidemia (pH less than 7.1 and serum bicarbonate 6 <span class=\"nowrap\">mEq/L</span> or less), receive <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> therapy. (See <a href=\"#H12631281\" class=\"local\">'Which patients should receive bicarbonate therapy'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The goal of bicarbonate therapy in patients with lactic acidosis and severe acidemia is to maintain the arterial pH above 7.1 until the primary process causing the metabolic acidosis can be reversed. (See <a href=\"#H12631289\" class=\"local\">'Therapeutic goal'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In adequately ventilated patients with lactic acidosis and severe acidemia, we give 1 to 2 <span class=\"nowrap\">mEq/kg</span> <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> as an intravenous bolus. We repeat this dose after 30 to 60 minutes if the pH is still less than 7.1. (See <a href=\"#H12631304\" class=\"local\">'Approach'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Rapid infusions of <a href=\"topic.htm?path=sodium-bicarbonate-drug-information\" class=\"drug drug_general\">sodium bicarbonate</a> may increase the PCO2, accelerate the production of lactate, lower the ionized calcium, expand the extracellular space, and raise the serum sodium concentration. (See <a href=\"#H12631806\" class=\"local\">'Potential harms of bicarbonate and alternative agents'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>There is little evidence that any alternative buffering agents are superior to bicarbonate therapy. (See <a href=\"#H12631806\" class=\"local\">'Potential harms of bicarbonate and alternative agents'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/1\" class=\"nounderline abstract_t\">Kraut JA, Kurtz I. Use of base in the treatment of severe acidemic states. Am J Kidney Dis 2001; 38:703.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/2\" class=\"nounderline abstract_t\">Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. Chest 2000; 117:260.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/3\" class=\"nounderline abstract_t\">Stacpoole PW. Lactic acidosis: the case against bicarbonate therapy. Ann Intern Med 1986; 105:276.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/4\" class=\"nounderline abstract_t\">Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36:222.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/5\" class=\"nounderline abstract_t\">Kraut JA, Madias NE. Treatment of acute metabolic acidosis: a pathophysiologic approach. Nat Rev Nephrol 2012; 8:589.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/6\" class=\"nounderline abstract_t\">Marsh JD, Margolis TI, Kim D. Mechanism of diminished contractile response to catecholamines during acidosis. Am J Physiol 1988; 254:H20.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/7\" class=\"nounderline abstract_t\">Mitchell JH, Wildenthal K, Johnson RL Jr. The effects of acid-base disturbances on cardiovascular and pulmonary function. Kidney Int 1972; 1:375.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/8\" class=\"nounderline abstract_t\">Teplinsky K, O'Toole M, Olman M, et al. Effect of lactic acidosis on canine hemodynamics and left ventricular function. Am J Physiol 1990; 258:H1193.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/9\" class=\"nounderline abstract_t\">Orchard CH, Kentish JC. Effects of changes of pH on the contractile function of cardiac muscle. Am J Physiol 1990; 258:C967.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/10\" class=\"nounderline abstract_t\">Mathieu D, Neviere R, Billard V, et al. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med 1991; 19:1352.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/11\" class=\"nounderline abstract_t\">Orchard CH, Cingolani HE. Acidosis and arrhythmias in cardiac muscle. Cardiovasc Res 1994; 28:1312.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/12\" class=\"nounderline abstract_t\">Cooper DJ, Walley KR, Wiggs BR, Russell JA. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med 1990; 112:492.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/13\" class=\"nounderline abstract_t\">Weil MH, Rackow EC, Trevino R, et al. Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation. N Engl J Med 1986; 315:153.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/14\" class=\"nounderline abstract_t\">Adrogu&eacute; HJ, Rashad MN, Gorin AB, et al. Assessing acid-base status in circulatory failure. Differences between arterial and central venous blood. N Engl J Med 1989; 320:1312.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/15\" class=\"nounderline abstract_t\">Posner JB, Plum F. Spinal-fluid pH and neurologic symptoms in systemic acidosis. N Engl J Med 1967; 277:605.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/16\" class=\"nounderline abstract_t\">Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med 1986; 105:836.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/17\" class=\"nounderline abstract_t\">Hood VL, Tannen RL. Protection of acid-base balance by pH regulation of acid production. N Engl J Med 1998; 339:819.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/18\" class=\"nounderline abstract_t\">Lang RM, Fellner SK, Neumann A, et al. Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med 1988; 108:524.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/19\" class=\"nounderline abstract_t\">Nahas GG, Sutin KM, Fermon C, et al. Guidelines for the treatment of acidaemia with THAM. Drugs 1998; 55:191.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/20\" class=\"nounderline abstract_t\">Kallet RH, Jasmer RM, Luce JM, et al. The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM). Am J Respir Crit Care Med 2000; 161:1149.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/21\" class=\"nounderline abstract_t\">Weber T, Tschernich H, Sitzwohl C, et al. Tromethamine buffer modifies the depressant effect of permissive hypercapnia on myocardial contractility in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 162:1361.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/22\" class=\"nounderline abstract_t\">Filley GF, Kindig NB. Carbicarb, an alkalinizing ion-generating agent of possible clinical usefulness. Trans Am Clin Climatol Assoc 1985; 96:141.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/23\" class=\"nounderline abstract_t\">Shapiro JI, Elkins N, Logan J, et al. Effects of sodium bicarbonate, disodium carbonate, and a sodium bicarbonate/carbonate mixture on the PCO2 of blood in a closed system. J Lab Clin Med 1995; 126:65.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/24\" class=\"nounderline abstract_t\">Gazmuri RJ, von Planta M, Weil MH, Rackow EC. Cardiac effects of carbon dioxide-consuming and carbon dioxide-generating buffers during cardiopulmonary resuscitation. J Am Coll Cardiol 1990; 15:482.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/25\" class=\"nounderline abstract_t\">Bersin RM, Arieff AI. Improved hemodynamic function during hypoxia with Carbicarb, a new agent for the management of acidosis. Circulation 1988; 77:227.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/26\" class=\"nounderline abstract_t\">Blecic S, De Backer D, Deleuze M, et al. Correction of metabolic acidosis in experimental CPR: a comparative study of sodium bicarbonate, carbicarb, and dextrose. Ann Emerg Med 1991; 20:235.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/27\" class=\"nounderline abstract_t\">Kette F, Weil MH, von Planta M, et al. Buffer agents do not reverse intramyocardial acidosis during cardiac resuscitation. Circulation 1990; 81:1660.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/28\" class=\"nounderline abstract_t\">Leung JM, Landow L, Franks M, et al. Safety and efficacy of intravenous Carbicarb in patients undergoing surgery: comparison with sodium bicarbonate in the treatment of mild metabolic acidosis. SPI Research Group. Study of Perioperative Ischemia. Crit Care Med 1994; 22:1540.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/29\" class=\"nounderline abstract_t\">Park R, Arieff AI. Treatment of lactic acidosis with dichloroacetate in dogs. J Clin Invest 1982; 70:853.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/30\" class=\"nounderline abstract_t\">Stacpoole PW, Harman EM, Curry SH, et al. Treatment of lactic acidosis with dichloroacetate. N Engl J Med 1983; 309:390.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/31\" class=\"nounderline abstract_t\">Stacpoole PW, Wright EC, Baumgartner TG, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med 1992; 327:1564.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/32\" class=\"nounderline abstract_t\">Mori M, Yamagata T, Goto T, et al. Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. Brain Dev 2004; 26:453.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/33\" class=\"nounderline abstract_t\">Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99:989.</a></li><li><a href=\"https://www.uptodate.com/contents/bicarbonate-therapy-in-lactic-acidosis/abstract/34\" class=\"nounderline abstract_t\">Stacpoole PW, Nagaraja NV, Hutson AD. Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 2003; 43:683.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2294 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H12631328\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H25392892\" id=\"outline-link-H25392892\">INTRODUCTION</a></li><li><a href=\"#H12631273\" id=\"outline-link-H12631273\">OVERVIEW OF THERAPY</a></li><li><a href=\"#H12631281\" id=\"outline-link-H12631281\">WHICH PATIENTS SHOULD RECEIVE BICARBONATE THERAPY</a></li><li><a href=\"#H12631289\" id=\"outline-link-H12631289\">THERAPEUTIC GOAL</a></li><li><a href=\"#H12631806\" id=\"outline-link-H12631806\">POTENTIAL HARMS OF BICARBONATE AND ALTERNATIVE AGENTS</a><ul><li><a href=\"#H12632674\" id=\"outline-link-H12632674\">Potential harms of bicarbonate therapy</a><ul><li><a href=\"#H12632681\" id=\"outline-link-H12632681\">- Increased PCO2</a></li><li><a href=\"#H12632935\" id=\"outline-link-H12632935\">- Acceleration of lactate generation</a></li><li><a href=\"#H12632964\" id=\"outline-link-H12632964\">- Effects on calcium, sodium, and extracellular fluid volume</a></li></ul></li><li><a href=\"#H12631930\" id=\"outline-link-H12631930\">Alternatives to bicarbonate therapy</a><ul><li><a href=\"#H12632114\" id=\"outline-link-H12632114\">- Tromethamine</a></li><li><a href=\"#H12632121\" id=\"outline-link-H12632121\">- Carbicarb</a></li><li><a href=\"#H12632128\" id=\"outline-link-H12632128\">- Dichloroacetate</a></li></ul></li></ul></li><li><a href=\"#H12631304\" id=\"outline-link-H12631304\">APPROACH</a></li><li><a href=\"#H709696017\" id=\"outline-link-H709696017\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H12631328\" id=\"outline-link-H12631328\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-metabolic-acidosis\" class=\"medical medical_review\">Approach to the adult with metabolic acidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-lactic-acidosis\" class=\"medical medical_review\">Causes of lactic acidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=control-of-ventilation\" class=\"medical medical_review\">Control of ventilation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metformin-poisoning\" class=\"medical medical_review\">Metformin poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-fluid-and-electrolyte-disorders\" class=\"medical medical_society_guidelines\">Society guideline links: Fluid and electrolyte disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=therapies-of-uncertain-benefit-in-basic-and-advanced-cardiac-life-support\" class=\"medical medical_review\">Therapies of uncertain benefit in basic and advanced cardiac life support</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hypovolemia-or-hypovolemic-shock-in-adults\" class=\"medical medical_review\">Treatment of hypovolemia or hypovolemic shock in adults</a></li></ul></div></div>","javascript":null}